In 2023, 39 Biologics companies received 39 FDA inspections in North Carolina, according to the U.S. Food and Drug Administration (FDA).
This was the second highest number of inspections per type of company made by the FDA in North Carolina, equalling 17% of all inspections in 2023.
Of all the North Carolina companies involved in the Biologics sector, Avioq, Inc. and Charlotte Mecklenburg Hospital Authority received the most citations from the FDA in 2023.
The FDA routinely inspects facilities across the nation to determine if the workplaces and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly for businesses to consistently make smarter business decisions for the future.
The FDA is a government agency primarily responsible for monitoring the manufacturing and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
| Project Area | No Action Indicated | Voluntary Action Indicated | Official Action Indicated |
|---|---|---|---|
| Bioresearch Monitoring | 26 | 1 | — |
| Blood and Blood Products | 30 | 2 | — |
| Compliance: Devices | 10 | 16 | — |
| Drug Quality Assurance | 3 | 6 | — |
| Food Composition, Standards, Labeling and Econ | 36 | 8 | — |
| Foodborne Biological Hazards | 80 | 28 | 1 |
| Human Cellular, Tissue, and Gene Therapies | 12 | 4 | — |
| Postmarket Assurance: Devices | 20 | 5 | — |
| Tobacco Post-Market Activities | 10 | 1 | — |
| Vaccines and Allergenic Products | 12 | — | — |
